A phase I study of crizotinib in combination with enzalutamide in metastatic castration-resistant prostate cancer before or after progression on docetaxel - Stand Up To Cancer

Blog

Posted October 14, 2019

A phase I study of crizotinib in combination with enzalutamide in metastatic castration-resistant prostate cancer before or after progression on docetaxel

JOIN OUR COMMUNITY

Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Stand Up to Cancer

Thanks for signing up!
You will hear from us soon.